How much profit has ImpediMed made this year?
ImpediMed has made -20.94 M AUD this year.
ImpediMed Net Income 2024
ImpediMed Net Income
-20.94 M AUD
Ticker
IPD.AX
ISIN
AU000000IPD8
In 2024, ImpediMed's profit amounted to -20.94 M AUD, a 2.06% increase from the -20.52 M AUD profit recorded in the previous year.
The ImpediMed Net Income history
| YEAR | NET INCOME (undefined AUD) |
|---|---|
| 2028e | - |
| 2027e | - |
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
| 2009 | - |
| 2008 | - |
| 2007 | - |
| 2006 | - |
| 2005 | - |
ImpediMed Revenue, EBIT, Net Income AU000000IPD8 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into ImpediMed, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ImpediMed from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ImpediMed’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of ImpediMed. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into ImpediMed’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing ImpediMed’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ImpediMed’s growth potential.
ImpediMed Revenue, EBIT and net profit per share
| Date | ImpediMed Revenue | ImpediMed EBIT | ImpediMed Net Income |
|---|---|---|---|
| 2028e | 68.58 M AUD | 0 AUD | 0 AUD |
| 2027e | 48.34 M AUD | 0 AUD | 0 AUD |
| 2026e | 31.07 M AUD | -3.67 M AUD | -4.09 M AUD |
| 2025e | 18.31 M AUD | -14.8 M AUD | -17.88 M AUD |
| 2024e | 11.51 M AUD | -22.12 M AUD | -20.94 M AUD |
| 2023 | 11.34 M AUD | -21.26 M AUD | -20.52 M AUD |
| 2022 | 10.57 M AUD | -19.85 M AUD | -19.87 M AUD |
| 2021 | 8.41 M AUD | -21.23 M AUD | -20.71 M AUD |
| 2020 | 5.74 M AUD | -22.9 M AUD | -21.38 M AUD |
| 2019 | 4.16 M AUD | -24.31 M AUD | -24.12 M AUD |
| 2018 | 3.32 M AUD | -27.65 M AUD | -27.37 M AUD |
| 2017 | 6.13 M AUD | -27.5 M AUD | -27.57 M AUD |
| 2016 | 5.95 M AUD | -23.66 M AUD | -25.98 M AUD |
| 2015 | 4.93 M AUD | -14.8 M AUD | -14.8 M AUD |
| 2014 | 3.58 M AUD | -7.95 M AUD | -7.94 M AUD |
| 2013 | 2.93 M AUD | -8.42 M AUD | -8.46 M AUD |
| 2012 | 3.18 M AUD | -12.71 M AUD | -12.34 M AUD |
| 2011 | 4.17 M AUD | -11.91 M AUD | -14.82 M AUD |
| 2010 | 3.81 M AUD | -11.34 M AUD | -11.4 M AUD |
| 2009 | 3.27 M AUD | -13.68 M AUD | -14.03 M AUD |
| 2008 | 2.99 M AUD | -8.06 M AUD | -9.76 M AUD |
| 2007 | 1.94 M AUD | -7 M AUD | -10.13 M AUD |
| 2006 | 1.08 M AUD | -4.94 M AUD | -7.58 M AUD |
| 2005 | 440,000 AUD | -3.23 M AUD | -3.19 M AUD |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 440,000 AUD | -3.23 M AUD | -3.19 M AUD |
| 2006 | 1.08 M AUD | -4.94 M AUD | -7.58 M AUD |
| 2007 | 1.94 M AUD | -7 M AUD | -10.13 M AUD |
| 2008 | 2.99 M AUD | -8.06 M AUD | -9.76 M AUD |
| 2009 | 3.27 M AUD | -13.68 M AUD | -14.03 M AUD |
| 2010 | 3.81 M AUD | -11.34 M AUD | -11.4 M AUD |
| 2011 | 4.17 M AUD | -11.91 M AUD | -14.82 M AUD |
| 2012 | 3.18 M AUD | -12.71 M AUD | -12.34 M AUD |
| 2013 | 2.93 M AUD | -8.42 M AUD | -8.46 M AUD |
| 2014 | 3.58 M AUD | -7.95 M AUD | -7.94 M AUD |
| 2015 | 4.93 M AUD | -14.8 M AUD | -14.8 M AUD |
| 2016 | 5.95 M AUD | -23.66 M AUD | -25.98 M AUD |
| 2017 | 6.13 M AUD | -27.5 M AUD | -27.57 M AUD |
| 2018 | 3.32 M AUD | -27.65 M AUD | -27.37 M AUD |
| 2019 | 4.16 M AUD | -24.31 M AUD | -24.12 M AUD |
| 2020 | 5.74 M AUD | -22.9 M AUD | -21.38 M AUD |
| 2021 | 8.41 M AUD | -21.23 M AUD | -20.71 M AUD |
| 2022 | 10.57 M AUD | -19.85 M AUD | -19.87 M AUD |
| 2023 | 11.34 M AUD | -21.26 M AUD | -20.52 M AUD |
| 2024e | 11.51 M AUD | -22.12 M AUD | -20.94 M AUD |
| 2025e | 18.31 M AUD | -14.8 M AUD | -17.88 M AUD |
| 2026e | 31.07 M AUD | -3.67 M AUD | -4.09 M AUD |
| 2027e | 48.34 M AUD | 0 AUD | 0 AUD |
| 2028e | 68.58 M AUD | 0 AUD | 0 AUD |
ImpediMed stock margins AU000000IPD8 ·
The ImpediMed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ImpediMed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ImpediMed.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the ImpediMed's sales revenue. A higher gross margin percentage indicates that the ImpediMed retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the ImpediMed's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the ImpediMed's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ImpediMed's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ImpediMed. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ImpediMed's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
ImpediMed Margin History
| ImpediMed Gross margin | ImpediMed Profit margin | ImpediMed EBIT margin | ImpediMed Profit margin |
|---|---|---|---|
| 2028e | 86.37 % | 0 % | 0 % |
| 2027e | 86.37 % | 0 % | 0 % |
| 2026e | 86.37 % | -11.81 % | -13.16 % |
| 2025e | 86.37 % | -80.83 % | -97.67 % |
| 2024e | 86.37 % | -192.26 % | -182.04 % |
| 2023 | 86.37 % | -187.39 % | -180.9 % |
| 2022 | 83.83 % | -187.84 % | -188.09 % |
| 2021 | 80.95 % | -252.46 % | -246.24 % |
| 2020 | 70.77 % | -398.95 % | -372.36 % |
| 2019 | 69.87 % | -584.94 % | -580.44 % |
| 2018 | 70.58 % | -833.36 % | -824.95 % |
| 2017 | 75.72 % | -448.44 % | -449.55 % |
| 2016 | 73.38 % | -397.85 % | -436.86 % |
| 2015 | 73.13 % | -300.45 % | -300.32 % |
| 2014 | 59.78 % | -222.07 % | -221.79 % |
| 2013 | 59.73 % | -287.37 % | -288.74 % |
| 2012 | 60.38 % | -399.69 % | -388.05 % |
| 2011 | 60.43 % | -285.61 % | -355.4 % |
| 2010 | 57.74 % | -297.64 % | -299.21 % |
| 2009 | 55.35 % | -418.35 % | -429.05 % |
| 2008 | 76.92 % | -269.57 % | -326.42 % |
| 2007 | 67.53 % | -360.82 % | -522.16 % |
| 2006 | 50.93 % | -457.41 % | -701.85 % |
| 2005 | 63.64 % | -734.09 % | -725 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 63.64 % | -734.09 % | -725 % |
| 2006 | 50.93 % | -457.41 % | -701.85 % |
| 2007 | 67.53 % | -360.82 % | -522.16 % |
| 2008 | 76.92 % | -269.57 % | -326.42 % |
| 2009 | 55.35 % | -418.35 % | -429.05 % |
| 2010 | 57.74 % | -297.64 % | -299.21 % |
| 2011 | 60.43 % | -285.61 % | -355.4 % |
| 2012 | 60.38 % | -399.69 % | -388.05 % |
| 2013 | 59.73 % | -287.37 % | -288.74 % |
| 2014 | 59.78 % | -222.07 % | -221.79 % |
| 2015 | 73.13 % | -300.45 % | -300.32 % |
| 2016 | 73.38 % | -397.85 % | -436.86 % |
| 2017 | 75.72 % | -448.44 % | -449.55 % |
| 2018 | 70.58 % | -833.36 % | -824.95 % |
| 2019 | 69.87 % | -584.94 % | -580.44 % |
| 2020 | 70.77 % | -398.95 % | -372.36 % |
| 2021 | 80.95 % | -252.46 % | -246.24 % |
| 2022 | 83.83 % | -187.84 % | -188.09 % |
| 2023 | 86.37 % | -187.39 % | -180.9 % |
| 2024e | 86.37 % | -192.26 % | -182.04 % |
| 2025e | 86.37 % | -80.83 % | -97.67 % |
| 2026e | 86.37 % | -11.81 % | -13.16 % |
| 2027e | 86.37 % | 0 % | 0 % |
| 2028e | 86.37 % | 0 % | 0 % |
ImpediMed Aktienanalyse
What does ImpediMed do?
ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding ImpediMed's Profit Margins
The profit margins of ImpediMed represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of ImpediMed's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating ImpediMed's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
ImpediMed's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When ImpediMed’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about ImpediMed stock
How has the profit developed compared to last year?
The profit has increased by 2.06% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does ImpediMed publish its earnings?
ImpediMed publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of ImpediMed?
The profits of ImpediMed are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of ImpediMed?
You can learn more about the earnings of ImpediMed by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does ImpediMed pay?
Over the past 12 months, ImpediMed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImpediMed is expected to pay a dividend of 0 AUD.
What is the dividend yield of ImpediMed?
The current dividend yield of ImpediMed is .
When does ImpediMed pay dividends?
ImpediMed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImpediMed?
ImpediMed paid dividends every year for the past 0 years.
What is the dividend of ImpediMed?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImpediMed located?
ImpediMed is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImpediMed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImpediMed from 9/12/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.
When did ImpediMed pay the last dividend?
The last dividend was paid out on 9/12/2024.
What was the dividend of ImpediMed in the year 2023?
In the year 2023, ImpediMed distributed 0 AUD as dividends.
In which currency does ImpediMed pay out the dividend?
The dividends of ImpediMed are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImpediMed
Our stock analysis for ImpediMed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImpediMed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
